A Prediction Model of Hematological Recovery After High-dose Chemotherapy in Pediatric Solid Tumor

Sponsor
Samsung Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT05024331
Collaborator
(none)
10
1
13
23.4

Study Details

Study Description

Brief Summary

This study aims to compare and evaluate the predicted values of the participants, and the algorithm predicted values of ANC level reduction periods after high-capacity chemotherapy in pediatric solid tumor patients. The participants are pediatricians who voluntarily participate in this study and consent to this study.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    n pediatric patients with solid tumors, chemotherapy for radical treatment is generally based on monitoring white blood cells, red blood cells, and platelets with repeated blood tests during treatment due to bone marrow depression.

    Early blood culture and experiential intravenous antibiotics are required to prevent progression to sepsis if fever or other infection signs are accompanied by a decrease in absolute neutrophil count (ANC) below 500/mm3. In addition, repeated blood transfusions are needed to keep the appropriate levels constant depending on clinical symptoms in platelet reduction or anemia.

    In particular, in the case of high-dose chemotherapy conducted on high-risk tumors, anticancer drugs are given over the dose expected to recover natural bone marrow function to improve the treatment performance of tumors responding to chemotherapy. Moreover, it is challenging to recover naturally after high-dose chemotherapy so that the collected in advanced hematopoietic stem cells are implanted into the patient to support ANC level recovery.

    However, despite the transplantation of these self-hematopoietic stem cells, some patients need long-term continuous blood transfusions due to delayed hematological recovery and may need long-term hospitalization to treat accompanying infections and complications.

    The researcher developed a model that can predict the suppression and hematological recovery of bone marrow after high-capacity anticancer drugs by analyzing blood tests and blood transfusions repeatedly from the diagnosis of pediatric solid tumors after high-capacity chemotherapy collected from 2000-2018.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    10 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Retrospective
    Official Title:
    A Prediction Model of Hematological Recovery After High-dose Chemotherapy in Pediatric Solid Tumor : Data Collection and Model Validation
    Actual Study Start Date :
    Jul 30, 2021
    Actual Primary Completion Date :
    Jul 30, 2021
    Actual Study Completion Date :
    Aug 12, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    Pediatric physicians

    Assigned Interventions Prediction of the first date of recovery period with given data about chemotherapy of pediatric patients who diagnosed solid tumor at Samsung medical center during 2010-2018 Sees the result of the prediction algorithm. Change or maintain their prediction values. Participate in the usability questionnaires.

    Outcome Measures

    Primary Outcome Measures

    1. accuracy of algorithm [This clinical trial is conducted in one day, and the Survey is conducted after completing the test using data from 99 pediatric patients.]

      primary outcome is the difference between result of algorithm and prediction values of doctors. total number of pediatric patients who performed chemotherapy and high-capacity chemotherapy at Samsung Medical Center in 2019-2020 - (Exclusion such as insufficient data or death) +10 reliability check questions expected to be approximately 100 questions The test based on data consisting of blood test results from approximately 100 patients, is recorded in anticipation of the first date (recovery date) of a day when ANC levels over 500 last more than 3 days.

    2. A quantitative study on usability [This clinical trial is conducted in one day, and the Survey is conducted after completing the test using data from 99 pediatric patients.]

      We would like to ask 17 questions to identify the user's thoughts on AI and how they affect change of opinion. The following are examples are as follows: Do you think you can easily adapt to new technologies or programs? Do you value subjective thoughts and experiences over other people's opinions in your work? Do you tend to browse information online when making decisions during work? Apart from this study, are you positive about the use of predictive models in clinical trials? Do you think the items and information in the given data are sufficient to predict the values you want to predict?

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • physician who is working at Samsung Medical Center as a pediatric doctor

    • A person who voluntarily agrees to participate in the study

    Exclusion Criteria:
    • Those who disagree with the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Samsung Medical Centre Seoul Korea, Republic of 06351

    Sponsors and Collaborators

    • Samsung Medical Center

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Samsung Medical Center
    ClinicalTrials.gov Identifier:
    NCT05024331
    Other Study ID Numbers:
    • 2021-02-059
    First Posted:
    Aug 27, 2021
    Last Update Posted:
    Sep 13, 2021
    Last Verified:
    Jul 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Samsung Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 13, 2021